The Role of Vitamin E in Peyronie’s Disease
DOI:
https://doi.org/10.55175/cdk.v45i10.712Kata Kunci:
Peyronie’s Disease, Antioxidant, treatment, vitamin EAbstrak
Peyronie’s disease (PD) is a disorder of tunica albuginea of corpus cavernosum characterized by the formation of plaque and fibrosis. Oral therapy is a promising non-operative modality. Vitamin E as a well-known antioxidant, is the oldest substance used since 1948 to treat Peyronie’s disease. The mechanism is to inhibit the production of inflammatory reactive oxygen species (ROS). There is still controversy over the effectiveness of vitamin E in Peyronie’s disease management.
Penyakit Peyronie merupakan gangguan jaringan ikat tunica albuginea dari corpus cavernosum yang mempunyai karakteristik pembentukan plak dan fibrosis. Terapi oral merupakan modalitas terapi non operatif yang menjanjikan. Vitamin E sebagai antioksidan yang sudah banyak dikenal, merupakan terapi tertua sejak tahun 1948. Mekanismenya adalah untuk menghambat produksi reactive oxygen species (ROS). Sampai saat ini efektivitas vitamin E dalam penanganan penyakit Peyronie masih kontroversial.
Unduhan
Referensi
Hussein A, Alwaal A, Luea T. All about Peyronie’s disease. Asian J Urol 2015;2(2):70-8.
Hatzimouratidis K, Giuliano F, Muneer A, Salonia A, Verze P, Moncada I. Erectile dysfunction, premature ejaculation, penile curvature and priapism. EAU Guidelines 2016. pp.32-43.
Somers KD, Dawson DM. Fibrin deposition in Peyronie’s disease plaque. J Urol 1997;157:311-5.
Vanni AJ, Bennett NE. Current treatment and management of the acute phase of Peyronies’s disease. Arch ESP Urol 2009;62, 614–22.
Hellstrom W. Medical Management of Peyronie’s disease. J Androl 2009;30(4): 397-405.
Scardino PL, Scott WW.The use of tocopherols in the treatment of Peyronie’s disease. Ann NY Acad Sci 1949;52(3):390–6.
Pryor JP, Farrell CF. Controlled clinical trial of vitamin E in Peyronie’s disease. Prog Reprod Biol 1983;9:1–45.
Safarinejad M. POS-01.89: Comparison of vitamin E and propionyl-l-carnitine, separately or in combination in patients with early chronic Peyronie’s disease: a double blind, placebo-controlled, randomized study. Urology 2007;70(3):217
Paulis G, Brancato T, D’Ascenzo R, De Giorgio G, Nupieri P, Orsolini G, Alvaro R. Efficacy of vitamin E in the conservative treatment of Peyronie’s disease: legend or reality? A controlled study of 70 cases. Andrology 2012;1(1):120-8.
Paulis G, Paulis A, Romano G, Barletta D, Fabiani A. Rationale of combination therapy with antioxidants in medical management of Peyronie disease: results of clinical application. Res Reports in Urology 2017; 9:129-39.
Sikk, S, Hellstrom W. Role of oxidative stress and antioxidants in Peyronie’s disease. Internat J Impotence Res 2002;14(5):353-60.
Paulis G, Romano G, Paulis L, Barletta D. Recent pathophysiological aspects of Peyronie’s disease: Role of free radicals, rationale, and therapeutic implications for antioxidant treatment—literature review. Advances in Urology 2017:1-17.
Joice G, Burnett A. Nonsurgical interventions for Peyronie’s disease: Update as of 2016. The World J Men’s Health 2016;34(2): 65.
Campbell J, Alzubaidi R. Understanding the cellular basis and pathophysiology of Peyronie’s disease to optimize treatment for erectile dysfunction. Translat Androl Urol 2017;6(1:46-59.
Barrett-Harlow B, Wang R. Oral therapy for Peyronie’s disease, does it work?. Translat Androl Urol 2016;5(3):296-302.
Prieto Castro R, Leva Vallejo M, Regueiro Lopez J, Anglada Curado F, Alvarez Kindelan J, Requena Tapia M. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Internat 2003;91(6):522-4.
Inal T, Tokatli Z, Akand M, Özdiler E, Yaman Ö. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie’s disease: A randomized and prospective study. Urology 2006;67(5):1038-42.
Nehra A. et al. Peyronie’s Disease: AUA. American Urological Association (AUA) Guideline 2015. pp.10-11.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
